Compare TRDA & ALLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRDA | ALLT |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 386.8M | 429.1M |
| IPO Year | 2021 | 2006 |
| Metric | TRDA | ALLT |
|---|---|---|
| Price | $10.29 | $9.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $20.00 | $12.75 |
| AVG Volume (30 Days) | 167.3K | ★ 401.2K |
| Earning Date | 11-06-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | $61,520,000.00 | ★ $98,512,000.00 |
| Revenue This Year | N/A | $12.08 |
| Revenue Next Year | $3.14 | $12.38 |
| P/E Ratio | ★ N/A | $456.22 |
| Revenue Growth | N/A | ★ 7.51 |
| 52 Week Low | $4.93 | $4.37 |
| 52 Week High | $18.76 | $11.42 |
| Indicator | TRDA | ALLT |
|---|---|---|
| Relative Strength Index (RSI) | 53.45 | 57.35 |
| Support Level | $9.89 | $9.06 |
| Resistance Level | $11.55 | $9.95 |
| Average True Range (ATR) | 0.51 | 0.40 |
| MACD | -0.21 | 0.05 |
| Stochastic Oscillator | 25.90 | 67.71 |
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.